MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide

Breast Cancer Research and Treatment

Volumn 132, Issue 3, 2012, Pages 947-953

  Okishiro, Masatsugu ^a   Kim, Seung Jin ^a   Tsunashima, Ryo ^a   Nakayama, Takahiro ^a   Shimazu, Kenzo ^a   Shimomura, Atsushi ^a   Maruyama, Naomi ^a   Tamaki, Yasuhiro ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; FEC100; MDM2 SNP309; Neutropenia; TP53 R72P

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR; PROTEIN MDM2; PROTEIN P53; ANTINEOPLASTIC AGENT; MDM2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

AGE DISTRIBUTION; ARTICLE; BODY SURFACE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; FEBRILE NEUTROPENIA; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MDM2 GENE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DNA SEQUENCE; FEMALE; FEVER; GENETICS; MIDDLE AGED; MISSENSE MUTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FEVER; FLUOROURACIL; GENETIC ASSOCIATION STUDIES; HUMANS; MIDDLE AGED; MUTATION, MISSENSE; NEUTROPENIA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865174672     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1637-5     Document Type: Article

References (24)

1. Roche H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for nodepositive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24:5664-5671
2. Mouret-Reynier MA, Abrial CJ, Ferrière JP et al (2004) Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at Centre Jean Perrin. Clin Breast Cancer 5:303-307
3. French Adjuvant Study Group (2001) Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5 year followup results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19:602-611
4. Abe H, Umeda T, Tanaka M et al (2010) Feasibility of FEC 100 followed by DOC 100 as adjuvant chemotherapy for breast cancer. Gan To Kagaku Ryoho 37:1483-1487
5. Toi M, Nakamura S, Kuroi K et al (2008) Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 110:531-539
6. Nayak MS, Yang JM, Hait WN (2007) Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res 67:5831-5839
7. Tommiska J, Eerola H, Heinonen M et al (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098-5103
8. Xu Y, Yao L, Ouyang T et al (2005) p53 codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 11:7328-7333
9. Xu Y, Yao L, Zhao A et al (2008) Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status. Int J Cancer 122:2761-2766
10. Toyama T, Zhang Z, Nishio M et al (2007) Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 9:R34
11. Dumont P, Leu JI, Della Pietra AC 3rd, George D, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365
12. Sullivan A, Syed N, Gasco M et al (2004) Polymorphism in wildtype p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23:3328-3337
13. Schmidt MK, Tommiska J, Broeks et al (2009) Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res 11:R89
14. Boersma BJ, Howe TM, Goodman JE et al (2006) Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98:911-919
15. Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205
16. Tsuda H, Sasano H, Akiyama F et al (2002) Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by herceptest, nichirei polyclonal antibody, CB11 and TAB 250 in breast carcinoma. Pathol Int 52:126-134
17. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403-410
18. Khrunin AV, Moisseev A, Gorbunova V, Limborska S (2010) Genetic polymorphisms and the efficacy and toxicity of cisplatinbased chemotherapy in ovarian cancer patients. Pharmacogenomics J 10:54-61
19. O'Connor PM, Jackman J, Bae I et al (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300
20. Kandioler-Eckersberger D, Ludwig C, Rudas M et al (2000) TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6:50-56
21. Chrisanthar R, Knappskog S, Løkkevik E et al (2008) CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One 26:e3062
22. Geisler S, Lønning PE, Aas T et al (2001) Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 6:2505-2512
23. Bunz F, Hwang PM, Torrance C et al (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263-269
24. Bertheau P, Turpin E, Rickman DS et al (2007) Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 4:e90